Asbestos related pleural malignant mesothelioma-18F-FDG PET/CT findings-

对石棉相关胸膜疾病患者进行18F-FDG PET/CT和血浆骨桥蛋白水平分析。6例经组织学证实为恶性胸膜间皮瘤（MPM）。在11例患者中，该病被认为是良性胸膜疾病。4例患者证实为石棉胸膜炎。其余7例患者证实有胸膜斑块。三组石棉相关胸膜疾病患者血浆骨桥蛋白水平和SUVmax有显著差异。MPM患者与石棉胸膜炎患者以及MPM患者与胸膜斑块患者之间的SUVmax存在显著差异。然而，MPM患者与石棉胸膜炎患者、MPM患者与胸膜斑块患者血浆骨桥蛋白水平无显著差异。良性石棉相关疾病患者的SUVmax与同一组血浆骨桥蛋白水平相关性良好，但MPM患者的SUVmax与同一组血浆骨桥蛋白水平无相关性。PET/CT可能比血浆骨桥蛋白更有助于区分良性石棉相关胸膜疾病和MPM，良性石棉相关胸膜疾病的SUVmax可能反映胸膜炎症的变化。

Analysis of 18F-FDG PET/CT and plasma osteopontin levels were performed in asbestos-related pleural disease patients. Six patients had histologically proven malignant pleural mesothelioma (MPM). In 11 patients, the disease was considered benign pleural disease. Four patients had proven asbestos pleurisy. The remaining 7 patients had proven pleural plaques. Significant differences were found among the three groups of asbestos-related pleural diseases for the plasma osteopontin levels and the SUVmax. Significant differences in the SUVmax were found between patients with MPM and those with asbestos pleurisy and between patients with MPM and patients with pleural plaques. However, there was no significant difference in the plasma osteopontin levels between patients with MPM and patients with asbestos pleurisy or between patients with MPM and patients with pleural plaques. The SUVmax in patients with benign asbestos-related diseases correlated well with plasma osteopontin levels in the same group, but the SUVmax in patients with MPM did not correlate with plasma osteopontin levels in the same group. PET/CT might be more helpful in distinguishing benign asbestos-related pleural diseases from MPM than plasma osteopontin, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.